U.S., July 24 -- ClinicalTrials.gov registry received information related to the study (NCT07081035) titled 'Trial of Low-intensity Anticoagulation to Reduce GI or Other Bleeding Complications With Equivalent Therapeutic Efficacy in HeartMate 3 LVAD Patients' on July 15.

Brief Summary: The TARGET trial is a prospective, single-center, randomized, open-label, active-controlled inequality clinical trial designed to evaluate the safety and efficacy of low-intensity anticoagulation therapy (target INR 1.5-2.0) compared to standard anticoagulation therapy (target INR 2.0-3.0) in patients receiving a HeartMate 3 Left Ventricular Assist Device (LVAD).

Despite the demonstrated effectiveness of HeartMate 3 LVAD in reducing thromboembolic complicat...